Dragomabin
Appearance
Identifiers | |
---|---|
| |
3D model (JSmol)
|
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C37H51N5O6 | |
Molar mass | 661.844 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Dragomabin is a lipopeptide isolated from the marine cyanobacteria Lyngbya majuscula.[1] It has in vitro antimalarial activity.[1] In 2018, a laboratory synthesis of dragomabin was reported.[2] The synthesis identified a misassignment of the configuration of the stereogenic center on the alkyne-bearing fragment and it was revised from (S) to (R).[2]
References
[edit]- ^ a b McPhail, Kerry L.; Correa, Jhonny; Linington, Roger G.; González, José; Ortega-Barría, Eduardo; Capson, Todd L.; Gerwick, William H. (June 2007). "Antimalarial Linear Lipopeptides from a Panamanian Strain of the Marine Cyanobacterium". Journal of Natural Products. 70 (6): 984–988. doi:10.1021/np0700772. PMC 2745555. PMID 17441769.
- ^ a b Ye, Baijun; Jiang, Peng; Zhang, Tingrong; Sun, Yuanjun; Hao, Xin; Cui, Yingjun; Wang, Liang; Chen, Yue (2018). "Total Synthesis of the Highly N-Methylated Peptides Carmabin a and Dragomabin". Marine Drugs. 16 (9): 338. doi:10.3390/md16090338. PMC 6164609. PMID 30227592.